KOKA Lifesciences Acquires Fangwei Medical, Improving its Heart Valve Devices

According to VCBeat, recently, KOKA Lifesciences, a technology company focused on the research and development of devices for heart valve interventions, completed the acquirement of Shanghai-based Fangwei Medical Technology Co., Ltd. ("Fangwei Medical"), an innovative company founded in 2019 mainly engaged in the research and development of mitral annuloplasty rings.

This acquisition will further accelerate the development of KOKA Lifesciences and improve its products to benefit more patients with a more professional product line.

Founded in 2018 with its R&D center located in Shanghai Zhangjiang Science City, KOKA Lifesciences is formed by a team from home and abroad engaged in the development of heart valve devices with rich experience. Based on technologies of precision machining, medical polymer membrane materials and blood hydrodynamics, KOKA Lifesciences has built the human body valve repair system. It provides solutions for valvular disease treatment for different people and clinical scenarios by using the technology of mitral valve repair and tricuspid valve repair. 

SuperClip, the mitral valve repair system developed by KOKA Lifesciences, has gone through the design and development of animal experiments and is ready to start large-scale clinical trials. Meanwhile, the research and development of other pipelines of the company, such as FlexClip mitral valve repair system and FlexClamp tricuspid valve repair system, has been completed and is currently under large-scale pre-clinical researches. In order to improve the function and competitiveness of products in the field of valve repair, Kekai Life Sciences decided to expand the pipelines to the field of annuloplasty mitral valve repair.

At present, the aging society has brought a large group of patients with mitral valve disease, and the treatment of mitral valve surgery has gradually changed from traditional surgery to minimally invasive and interventional therapy. The promotion of minimally invasive surgery is expected to improve patients' acceptance of mitral valve surgery, while interventional therapy with wider indications and less invasiveness will become the future trend.